ResearcherHarbin Medical UniversityNo recent work listed

Tao Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9835-4744; OpenAlex author ID A5100455265. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper

Papers 2

Pristimerin synergizes with gemcitabine through abrogating Chk1/53BP1-mediated DNA repair in pancreatic cancer cells. Last author DOI 10.1016/j.fct.2020.111919 ↗
Phosphatidylserine-exposing blood cells, microparticles and neutrophil extracellular traps increase procoagulant activity in patients with pancreatic cancer. First author DOI 10.1016/j.thromres.2020.01.025 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yanqing Liu · 1 shared paper, 2021 · strength 0.19
- Paper Pristimerin synergizes with gemcitabine through abrogating Chk1/53BP1-mediated DNA repair in pancreatic cancer cells. DOI 10.1016/j.fct.2020.111919 ↗
Zhuangzhuang Jiang · 1 shared paper, 2021 · strength 0.19
- Paper Pristimerin synergizes with gemcitabine through abrogating Chk1/53BP1-mediated DNA repair in pancreatic cancer cells. DOI 10.1016/j.fct.2020.111919 ↗
Jialan Shi · 1 shared paper, 2020 · strength 0.09
- Paper Phosphatidylserine-exposing blood cells, microparticles and neutrophil extracellular traps increase procoagulant activi… DOI 10.1016/j.thromres.2020.01.025 ↗
Muxin Yu · 1 shared paper, 2020 · strength 0.09
- Paper Phosphatidylserine-exposing blood cells, microparticles and neutrophil extracellular traps increase procoagulant activi… DOI 10.1016/j.thromres.2020.01.025 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.